CN Patent

CN101801347A — 包含二氢吡啶类钙通道拮抗剂的改进的药物组合物及其制备方法

Assigned to Athena Pharmaceutical Co ltd · Expires 2010-08-11 · 16y expired

What this patent protects

本发明涉及固体剂型的制剂，包括与用于提高生物利用度和改善溶解度的胶体二氧化硅例如Aerosil TM 相组合的治疗有效量的二氢吡啶类钙通道拮抗剂例如乐卡地平或其盐，还涉及通过湿法造粒来制备所述固体剂型制剂的方法。

USPTO Abstract

本发明涉及固体剂型的制剂，包括与用于提高生物利用度和改善溶解度的胶体二氧化硅例如Aerosil TM 相组合的治疗有效量的二氢吡啶类钙通道拮抗剂例如乐卡地平或其盐，还涉及通过湿法造粒来制备所述固体剂型制剂的方法。

Drugs covered by this patent

fingolimod-lauryl-sulfate (FINGOLIMOD LAURYL SULFATE)

Patent Metadata

Patent number: CN101801347A
Jurisdiction: CN
Classification: —
Expires: 2010-08-11
Drug substance claim: No
Drug product claim: No
Assignee: Athena Pharmaceutical Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.